CD40 and myeloid sarcoma: Although CD40‐targeted therapy for MS requires further large‐scale clinical trials to validate its long‐term efficacy, its dual capacity to modulate immune dysregulation and attenuate neuroinflammation offers promising therapeutic potential for MS patients.